吗替麦考酚酯、小剂量激素、拉米夫定联合治疗原发性肾病综合征合并慢性乙型病毒性肝炎的疗效

目的 探讨吗替麦考酚酯、小剂量激素、拉米夫定联合治疗原发性肾病综合征合并慢性乙型病毒性肝炎的疗效及临床病理关系.方法 回顾性分析73例采用吗替麦考酚酯、小剂量激素、拉米夫定联合治疗的原发性肾病综合征合并慢性乙型病毒性肝炎患者的临床资料.结果 73例中完全缓解51例,部分缓解13例,无效9例,总有效率87.7%(64/73).治疗时间最短12个月,最长36个月.随访12个月,血清HBV-DNA转阴率54.8%(40/73).微小病变(MCD)完全缓解率100.0%(8/8 ),膜性肾病(MN)完全缓解率20.0%(3/15),系膜增殖性肾炎(MsPGN)完全缓解率83.3%(25/30),局灶节段增殖性肾炎(FSPGN)完全缓解率93.7%(15/16 ),局灶节段肾小球硬化(FSGS)完全缓解率50.0%(2/4 ).至末次随访时,所有患者均无肝肾功能减退.结论 吗替麦考酚酯、小剂量激素、拉米夫定联合治疗原发性肾病综合征合并慢性乙型病毒性肝炎安全有效,必要时疗程可适当延长.疗程与病理类型有关,以MCD治疗反应最好,FSPGN、MsPGN、FSGS次之,MN较差.

Combined Treatment with Mycophenolate Mofetil,Low-dose Hormone,and Lamivudine for Primary Nephrotic Syndrome Associated with Chronic Hepatitis B

Objective To investigate the efficacy of combined treatment with mycophenolate mofetil(MMF),low-dose hormone,and lamivudine for primary nephrotic syndrome associated with chronic hepatitis B and its relationship with clinical pathology.Methods A retrospective analysis was performed in 73 patients with primary nephrotic syndrome and chronic hepatitis B who were treated with MMF,low-dose hormone,and lamivudine.Results Among the 73 patients,51 achieved complete remission,13 achieved partial remission and 9 sho...